At a glance
- Originator Novartis
- Class Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Craniocerebral trauma; Epilepsy; Stroke
Most Recent Events
- 19 Dec 1996 Discontinued-I for Epilepsy in Switzerland (PO)
- 19 Dec 1996 Discontinued-I for Head injuries in Switzerland (PO)
- 19 Dec 1996 Discontinued-I for Stroke in Switzerland (PO)